Tag: psoriatic arthritis

Psoriatic Arthritis: Tips for Managing

Medical treatment for your psoriatic arthritis (PsA) is essential for managing symptoms and protecting your joints. But alongside therapies and regular checkups, there are daily...

Biologic Treatment Mitigates PsA Risk in Patients With Psoriasis, Study Finds

Psoriasis patients treated with biological disease-modifying antirheumatic drugs had a significantly lower incidence of psoriatic arthritis (PsA) compared with those treated with phototherapy, in a...

Studies Highlight Pandemic’s Impact on Patients With RMDs

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Reduced access to medical care, increased mental health issues, poor lifestyle...

Fecal Transplantation Safe but Ineffective in PsA Trial

The first clinical trial of fecal microbiota transplantation in patients with psoriatic arthritis has found the procedure to be as safe as a sham procedure,...

Study Finds Psoriasis Associated With an Increased COVID-19 Risk

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. People with psoriasis have a higher risk of infection with COVID-19...

Bimekizumab Tops Adalimumab for Plaque Psoriasis

Bimekizumab bested adalimumab for moderate to severe plaque psoriasis in a phase 3 trial of adults from the agent’s maker UCB Pharma. The interleukin-17A (IL-17A)...

Psoriasis Clearance Rates Higher With Bimekizumab vs Secukinumab

Secukinumab is the latest adult plaque psoriasis treatment to be bested by a newcomer, the interleukin 17A and 17F blocker bimekizumab. Rates of complete clearance...

Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients

Patients taking methotrexate for psoriasis or psoriatic arthritis (PsA) were at a higher risk of developing liver disease than were patients with rheumatoid arthritis (RA)...

Tofacitinib Linked to Risk for Cardiac Events, Cancer, FDA Warns

The Food and Drug Administration has alerted the public to an increased risk of serious heart-related problems and cancer risk associated with the Janus kinase...

Tofacitinib for RA Misses the Mark in Safety Study

Daily treatment with tofacitinib (Xeljanz) led to more malignancies and adverse cardiovascular events in older rheumatoid arthritis patients compared with treatment with a tumor necrosis...

Pregnancy Studies on Psoriasis, PsA Medications Pick Up

Christina Chambers, PhD, MPH, who runs the MotherToBaby Pregnancy Studies research center at the University of California, San Diego, has found most pregnant women to...

Ustekinumab May Trigger Acute CV Events Early in Treatment

Initiating treatment with the interleukin-12/23p40–targeting monoclonal antibody ustekinumab may trigger early severe cardiovascular events (SCEs) in susceptible patients, according to a large French case-time-control analysis. Investigators...

The Long Road to a PsA Prevention Trial

About one-third of all patients with psoriasis will develop psoriatic arthritis (PsA), a condition that comes with a host of vague symptoms and no definitive...

Tailoring Treatment for Psoriasis, PsA, and Pregnancy

With an average age of diagnosis of 28 years, and one of two incidence peaks occurring at 15-30 years, psoriasis affects many women in the...